Use of the receptor GPR86
First Claim
Patent Images
1. A method of identifying a compound capable of binding to GPR86 polypeptide, the method comprising:
- (a) contacting a GPR86 polypeptide with a candidate compound; and
(b) determining whether the candidate compound binds to the GPR86 polypeptide;
wherein the compound is suitable for treating, preventing or alleviating inflammatory disease or pain in an individual, wherein the inflammatory disease or pain is associated with activity of GPR86.
2 Assignments
0 Petitions
Accused Products
Abstract
We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a GPR86 associated disease, in particular inflammatory disease or pain, the method comprising determining whether a candidate molecule is an agonist or antagonist of GPR86 polypeptide, in which the GPR86 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5 or SEQ ID NO: 7, a fragment thereof or a sequence which is at least 90% identical thereto.
-
Citations
30 Claims
-
1. A method of identifying a compound capable of binding to GPR86 polypeptide, the method comprising:
-
(a) contacting a GPR86 polypeptide with a candidate compound; and
(b) determining whether the candidate compound binds to the GPR86 polypeptide;
wherein the compound is suitable for treating, preventing or alleviating inflammatory disease or pain in an individual, wherein the inflammatory disease or pain is associated with activity of GPR86. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method of identifying a compound suitable for treating, preventing or alleviating inflammatory disease or pain comprising:
-
(a) administering a candidate compound capable of binding to GPR86 polypeptide to an animal, and (b) determining whether the animal exhibits (i) increased or decreased sensitivity to pain, or (ii) increased or decreased susceptibility to inflammatory pain, as compared with an animal to which the candidate compound has not been administered;
thereby identifying a compound for treating, preventing or alleviating inflammatory disease or pain. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22)
-
-
23. A method of identifying an antagonist of GPR86 polypeptide, the method comprising:
-
(a) administering a candidate compound capable of binding to GPR86 polypeptide to an animal; and
(b) determining whether the animal exhibits (i) decreased sensitivity to pain or (ii) decreased susceptibility to inflammatory pain, as compared with a wild type animal to which the candidate compound has not been administered, thereby identifying an antagonist of GPR86 polypeptide.
-
-
24. A method of identifying an agonist of GPR86 polypeptide the method comprising:
-
(a) administering a candidate compound capable of binding to GPR86 polypeptide to an animal; and
(b) determining whether the animal exhibits (i) increased sensitivity to pain, or (ii) increased susceptibility to inflammatory pain, as compared with a wild type animal to which the candidate compound has not been administered, thereby identifying an agonist of GPR86 polypeptide.
-
-
25. A method of treating an individual suffering from inflammatory disease or pain, wherein the inflammatory disease or pain is associated with GPR86 activity, the method comprising administering a modulator of GPR86 to the individual.
-
26. A method of diagnosing susceptibility to inflammatory disease or pain in an individual, wherein the inflammatory disease or pain is associated with GPR86 activity, the method comprising detecting a change in expression pattern or level of GPR86 in a cell or tissue of the individual.
-
27. A method of diagnosing susceptibility to inflammatory disease or pain in an individual, wherein the inflammatory disease or pain is associated with GPR86 activity, the method comprising detecting a polymorphism in a GPR86 polynucleotide in a cell or tissue of the individual.
-
28. The method of claim 31, wherein the GPR86 polynucleotide comprises a nucleic acid sequence shown in SEQ ID NO:
- 1, SEQ ID NO;
2, or SEQ ID NO;
4.
- 1, SEQ ID NO;
- 29. A transgenic non-human mammal comprising a disruption in the endogenous GPR86 gene, wherein the disruption results in a change in a biological parameter selected from the group consisting of response to stimuli, response to heat, response to light, an immune response, an inflammatory response, and response to pain, as compared to a wild type animal.
Specification